AEterna Zentaris Inc. (AEZS)

[Miraclestock]

Previous price targets about AEZS of $3 and $4 are now outdated. Macrilen now costs DOUBLE the price of previous price estimate on which current price targets are based. In addition, Macrilen is also being used in a much larger market than the current price targets are based on. Specifically, Macrilen is being expanded into Traumatic Brain Injury (TBI) market and not only AGHD market. TBI market had 600,000-700,000 eligible patients per year. I think that the 600,000-700,000 number is only for the USA and Canada. There are also TBI patients in Europe, Asia, and other places. The price targets in my opinion should be raised to at least $5-$8 based upon the new pricing of Macrilen and expanded Macrilen market announced yesterday.